Trials / Not Yet Recruiting
Not Yet RecruitingNCT07458269
Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 250 (estimated)
- Sponsor
- Kailera · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to determine the effects of KAI-9531 administered by subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KAI-9531 | SC Injection |
| DRUG | Placebo | SC Injection |
Timeline
- Start date
- 2026-03-01
- Primary completion
- 2027-05-01
- Completion
- 2027-06-01
- First posted
- 2026-03-09
- Last updated
- 2026-03-09
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07458269. Inclusion in this directory is not an endorsement.